Bioject Establishes Strategic Alliance with MPI Research
News Jan 06, 2010
Bioject Medical Technologies Inc. has announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics.
“Bioject and MPI Research share an innovative and entrepreneurial spirit that creates a synergy vital to our industry. It is a pleasure to collaborate with a company that has such highly-developed technological expertise and strategic vision.”
The strategic alliance creates a preferred partnership relationship which allows Bioject to gain access to a range of capabilities and resources needed for the company to explore our drug+device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research.
The strategic alliance offers MPI Research the opportunity to provide Bioject’s needle-free technology as an alternate delivery option to current drug/biologic manufacturers who may be interested in seeking a highly competitive and differentiable drug+device brand.
This alliance also increases the possibility that Bioject and MPI Research may be able to secure government sponsored grants or funding directed at improvements in drug+device or vaccine+device based treatments, which could also lead to potential new drug+device combinations.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE